We performed a systematic review of the available evidence on the relationship between the individual clinical, echocardiographic and laboratory characteristics of patients with atrial fibrillation (AF) and the risk of stroke. A systematic review was also performed of all published stroke risk stratification models, as well as the accuracy of their discriminative ability between risk strata. Third, we reviewed the literature on cost-effectiveness analyses with oral anticoagulation in AF. From the systematic review on stroke risk factors, a prior stroke or transient ischemic attack (15/16 studies positive, risk ratio [RR] 2.86), hypertension (11/20 studies positive, RR 2.27), aging (9/13 studies positive, RR 1.46 per decade increase), structural heart disease (9/13 studies positive, RR 2.0) and diabetes (9/14 studies positive, RR 1.62) were found to be good independent predictors of stroke. Supportive evidence was found for sex (8/22 studies positive, RR 1.67), vascular disease (6/17 studies positive, RR 2.61) and heart failure (7/18 studies positive, RR 1.85). The various risk stratification schemes classified variable proportions as low, moderate and high risk, but the CHA2DS2-VASc score classified the smallest proportion of patients as 'low risk'. Anticoagulation with vitamin K antagonists and dabigatran is cost-effective in patients at high risk of stroke, but not in patients without any other stroke risk factor beside AF. Continued efforts are warranted to improve the antithrombotic management of AF patients to identify, and challenge, risk factors and refine risk stratification models in order to realize an individualized tailored, risk factor-based approach. 
trial fibrillation (AF) is the most common sustained arrhythmia 1 and confers an independent risk of stroke and death. 2 The individual AF patient's risk of stroke depends on the presence of other demographic, clinical, biochemical and echocardiographic risk factors. 3, 4 Oral anticoagulation (OAC) with vitamin K antagonists (VKAs) reduces the incidence of stroke by 64% and mortality by 26% compared to control or placebo, and is superior compared to the protection offered by antiplatelet agents. 5 Recently, three novel OACs, 1 oral direct thrombin inhibitor (dabigatran) and 2 oral factor Xa inhibitors (rivaroxaban, apixaban), have been proven to match or even surpass the already impressive stroke risk reduction of VKAs. [6] [7] [8] Transforming the data on stroke risk factors in AF patients into a user-friendly format that would be suitable for everyday clinical practice has been the rationale behind the development of the many risk stratification models (RSMs). RSMs initially aimed to classify patients into clinically relevant stroke risk categories (high-, intermediate-and low-risk) that could subsequently facilitate the choice of the most appropriate antithrombotic treatment. However, in clinical practice this translated into identifying the 'high-risk' AF patients who could be targeted for the 'inconvenient' VKAs, whereas all other AF patients could be treated with the less effective therapy, aspirin (ie, low-and intermediate-risk patients, or those who refuse VKAs) or no therapy. [9] [10] [11] Over the past few years, a growing body of evidence has emerged to demonstrate that OAC, including VKAs, is beneficial even in patients with a 'moderate' stroke risk, including those with 1 stroke risk factor. 12, 13 Improvements in warfarin control, with a high percentage of time in therapeutic range (TTR), have contributed to lower bleeding rates (as well as low stroke rates). 14 Thus, there has been a paradigm shift towards identification of 'truly low risk' individuals with AF who do not need any antithrombotic therapy, and those with ≥1 stroke risk factors
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who can be offered effective stroke prevention, which essentially is OAC-whether with well-controlled warfarin or one of the new OACs. Thus, a stroke risk factor (and not a category)-based approach to thromboprophylaxis reflects current practice. 15, 16 In 2010, the European guidelines on the management of AF acknowledged the aforementioned evidence and subsequently adopted the revised, risk factor-based approach and emphasized that OAC is the recommended antithrombotic treatment for most patients with AF. 17 The present analysis aimed to systematically review (a) the independent risk factors for stroke in AF patients, (b) the published RSMs and (c) the published cost-effectiveness data of (new) oral anticoagulant and antiplatelet agents for stroke prevention in AF patients.
Methods
Studies were selected for review based on the published abstract content (or full paper if no abstract was available) by 2 of the authors (R.P. and G.Y.H.L.). They evaluated all studies to see if they met the inclusion criteria to be considered for review. In case of disagreement, a third author was consulted. All decisions to exclude a study were unanimous. Details of the study selection criteria, outcome measures, systematic review methodology for the stroke risk factors/risk stratification methods and the cost-effectiveness review are provided in Appendix S1.
Results

Stroke Risk Factors
The systematic literature search yielded a total of 3,154 records leading to review for inclusion based on the full article in 432, of which 405 were excluded (see PRISMA flowchart in Figure) . The remaining 27 studies were critically appraised. This systematic review allowed several studies that were derived from similar clinical trial populations to be included, because none of them used exactly the same populations or risk models.
Age Nine studies used a cut-off value (predominantly age ≥75 years) 15,18-25 and another 15 used increment per (half a) decade or age as a continuum for assessing its independent effect on stroke. 4,19,24,26- 35 Of the 24 studies, 17 reported age to be an independent risk of stroke, 4,19-23,25,27-29,33,34,36 whereas the other 7 studies did not ( Table 1) . 15 ,18,24,30-32, 40 A recent study by Hobbs et al studied the incremental risk per 5 years among 665 elderly patients (all aged ≥75 years) and did not reveal age to be an independent stroke risk factor. 30 However, the vast majority of the studies that looking at incremental risk per decade did find age to be an independent stroke risk factor. 19,24,27-29,33, 36 The evidence supporting age as an independent stroke risk factor also remains when it is considered for every decade of age increase, 20-23 with only 2 negative results in a very small, older cohort 18 and a mediumsize cohort of 1,577 patients across Europe. 15 Sex Of the 21 studies considering biological sex as a risk factor for stroke (Table 2) 39 Another older study identified male sex as an independent risk factor for stroke in paroxysmal AF patients. 20 Stroke, Transient Aschemic Attack (TIA) or Systemic Embolism All but one 15 of 16 studies considering a history of stroke or TIA and 1 study considering thromboembolism found it to be a significant independent risk factor for recurrent stroke (Table 3) . 4,21,24,25,28-30,33-36,38,40 Hypertension In total, 29 studies looked at whether hypertension was an independent stroke risk factor (Table 4) . 4 38 Left ventricular hypertrophy, defined as a left ventricular mass >110 g/m 2 in women and >134 g/m 2 in men, was found to be a significant independent risk factor for stroke in 2 studies. 38, 41 Chronic Kidney Disease Only 2 studies examined the relationship between chronic kidney disease and stroke, with 1 not demonstrating an independent association with the risk of stroke 21 and the other study reported a correlation between decreasing glomerular filtration rate and stroke risk in conjunction with proteinuria as an independent stroke risk factor. 43 Structural Heart Disease Structural heart disease in general was recently found not to be predictive of stroke in a UK primary care study considering valvular and congenital cardiac disease, 23 whereas an older, single study did show the predictive ability of structural heart disease 18 (Table 5A) . Valvular heart disease in general, and mitral stenosis specifically, were found to be independent risk factors for stroke in 2 studies, 25,38 but not in another, 30 and there was no relationship between annular calcification and stroke. 37 A meta-analysis of 3 clinical trials did not demonstrate that any degree of mitral valve prolapse or regurgitation was an independent predictor of stroke or thromboembolism. 34 A dilated left atrium 37 and increasing left atrial size per body surface area 26 were found to be independent stroke risk factors.
Vascular Disease Ischemic heart disease was not an independent stroke risk factor in 3 studies. 21,27 A similar conclusion was drawn from 2 other studies in respect to angina. 4, 30 History of myocardial infarction was considered in 6 studies, with 2 identifying 32,37 and 4 disputing 4,21,30,38 its predictive capability regarding stroke risk.
More recently, peripheral artery disease alone has been examined as a stroke risk factor in 2 cohorts, both identifying it as an independent stroke risk factor. 21, 23 Two other studies investigated vascular disease as a combination of peripheral artery and/or coronary artery disease, 15,44 with 1 reporting an independent relationship, 44 whereas the other 15 did not identify this combination of vascular disease to be an independent stroke risk factor.
Congestive Heart Failure (CHF) A history or current episode of CHF was considered as a risk factor for stroke in 12 studies. Other Risk Factors Table 5B provides an overview of the studies which considered other (predisposing factors of) car-PISTERS R et al. Of these, 2 studies failed to find that being a smoker was an independent risk factor for stroke. 4,23 Obesity was considered in 3 studies and only to be found predictive of stroke in one. One study considered alcohol abuse and hyperlipidaemia, but neither was found to be independent stroke risk factor. 23 Nine studies found diabetes mellitus to be an independent risk factor for stroke. 4,21,25,28,30,34, 36 Five other studies, 1 in a general population, 15 1 in patients with atrial flutter, 42 1 in an elderly cohort 38 and 2 in low-risk AF patients, 27,32 failed to find that diabetes mellitus was an independent stroke risk factor.
Hormone replacement therapy was found to independently Tables 1,2 . PISTERS R et al.
predict the risk of stroke in AF patients in 1 study, 28 but not another. 39 One population-based prospective study investigating whether or not the blood coagulation markers, von Willebrand factor, soluble P-selectin and fibrinogen were independent predictors of stroke and cardiovascular mortality in AF patients failed to demonstrate an independent risk for stroke associated with any of these parameters. 45 Another study identified Creactive protein as a predictor risk of stroke. 25 AF Type Paroxysmal vs. non-paroxysmal clinical type of AF was not found to independently predict stroke in any of the 3 studies that considered it. 18,33, 46 In only 1 study was a longer history of AF found to be an independent stroke risk factor. 24 
Stroke Risk Stratification Models
The same 3,154 abstracts were used for the systematic review of RSMs. The abstract and full text information led to the exclusion of 3,135 studies and inclusion of 19 studies. A general overview of all included studies in the systematic review of RSMs is shown in Table 6A .
First, the incorporation of independent risk factors of stroke derived from the systematic review of stroke risk factors into the RSMs was checked ( Table 6B ). The risk factors used in all RSMs were acknowledged to be independent risk factors of stroke by at least one of the studies from the systematic review, except for 2. 47, 48 These RSMs were both based on expert consensus. Although some definition of hypertension could be found in all RSMs, this was not the case for the strongest independent risk factor of stroke: prior stroke or thromboem- BMI, body mass index; CHF, congestive heart failure; DM, diabetes mellitus; NYHA, New York Heart Association heart failure stage; LV, left ventricular; MI, myocardial infarction; SHD, structural heart disease. Other abbreviations as in Tables 1,2 . Stroke Risk in AF 
bolism.
The systematic search of papers evaluating both internally and externally validated stroke risk models resulted in 12 stud- ies, 4,28,40,41,43,49-52 following exclusion of 1 study because of substratification by age group. 4 In total, 12 models were evaluated on 28 occasions.
When considering the 95% confidence intervals (CIs) for the observed stroke incidence of each risk category for each RSM, only one stroke risk model using 3 risk strata (low, moderate, high) reached separation of each risk group at the 95% CI level; that is, the Stroke Prevention in AF model. 28 The results of the studies found to have reported on discriminative capabilities of each RSM using the c-statistic are shown in Table 6C .
One recent study reported the values of the c-statistic for 9 RSMs within the same population and found the Rietbrock modified CHADS2-index to have the highest c-statistic. 30 The CHADS2 score was found to have the highest c-statistic in the same population in another study comparing 5 different RSMs. 52 The largest of all comparative studies, a nationwide cohort, found that the highest c-statistic for an evaluation of 2 RSMs using the same population was for the CHA2DS2-VASc score. 16 The various risk stratification schemes classified variable proportions as low, moderate and high risk, but in general, the CHA2DS2-VASc score classified the lowest proportion of patients as 'low risk'.
Cost-Effectiveness
An overview of studies looking into the cost-effectiveness of antithrombotic therapy for AF can be found in Table 7 .
Vitamin K Antagonists vs. No Anticoagulation Anticoagulation treatment in a general AF population was found to be relatively cost-effective compared to no anticoagulation in all 9 studies reporting on it. 53- 61 The incremental cost-effectiveness rate (ICER) in a British study ranged from £1,751 and £13,221 per life-year gained free from stroke, 56 which is comparable to reports from North America and Sweden during the same time period, reporting, US$1,907 and SKR171,000-417,000, respectively. The latter range depended on the perceived risk of bleeding being either low (0.3%) or more average (2%).
Caro et al found an annual reduction in total healthcare costs of US$1,514 if anticoagulation was used in AF patients. 53 Cost-effectiveness of VKAs also depends on the risk of stroke. In patients at low risk (ie, only AF as a stroke risk factor), there is no perceived benefit when they are treated with VKAs, expressed by the increased costs and decreased quality-adjusted life years (QALY), whereas patients with more than 2 of the classical risk factors of stroke do benefit, with an ICER of US$1,434 -£6,000 -per QALY. 54,55,57,60
Antiplatelet Therapy vs. Vitamin K Antagonists A UK study in a high risk, elderly (≥75 years) population found the total costs, associated with both hemorrhagic and thrombotic events, to be lower and QALY scores to be higher in patients receiving warfarin compared to those receiving aspirin. 62 Another study in less elderly AF patients with a 'moderate' to high stroke risk also demonstrated the cost-effectiveness of vitamin K antagonists over aspirin (ICER US$500/QALY). 55 Three other studies supported the cost-effectiveness of VKAs compared with aspirin. 53,54, 61 In addition to the stroke risk reduction playing an important role in treatment decisions, the quality of anticoagulation and discontinuation of the drug should also be considered. 59 The benefits for patients at low risk of stroke comes at the price of significantly increased costs over aspirin (US$370,000/QALY in 65-year-old patients and US$110,000/QALY in 75-year-old patients) compared to those at medium to high stroke risk (US$8,000/QALY). Also, bleeding risk was found to have a negative effect on the cost-effectiveness of VKAs. 55 Dabigatran vs. Vitamin K Antagonists or Antiplatelet Therapy Three studies reported on the cost-effectiveness of the new oral direct thrombin inhibitor, dabigatran, compared to other forms of antithrombotic therapy. 63- 65 One study found that, assuming an average risk of major bleeding, only aspirin was cost-effective for those at lowest risk of stroke (CHADS2 score=0). Unless the TTR was poor (<57.1%) or the risk of major bleeding increased, warfarin was cost-effective in those at moderate risk of stroke (CHADS2 score 1 or 2). Dabigatran 150 mg twice daily was cost-effective in those with a CHADS2 score >2, when the TTR was not excellent (>72.6%). 64 A lower dose (110 mg twice daily) of dabigatran and clopidogrel, in addition to aspirin, was not found to be cost-effective in this analysis. 64 From a Canadian perspective, dabigatran etexilate was found to be cost-effective compared to VKAs (ICER $10,440/QALY) in patients at moderate to high risk of stroke. 65 Another study found the price of dabigatran to be of importance, as the assumption of US$13,80 for the high (150 twice daily) dose resulted in an ICER of US$51,229/QALY for lowdose dabigatran and US$ 45,372/QALY for high-dose dabigatran. 63 
Discussion
This systematic review demonstrates that the strongest, independent predictors of stroke are a prior stroke or TIA, age >75 years, hypertension, diabetes mellitus and structural heart disease. Sex, heart failure and vascular disease cause more discussion because the available evidence favoring thier use as risk factors in AF per se is not as convincing. The interplay of less powerful independent risk factors of stroke could potentially help explain apparent differences in predictive ability of (clinical) entities such as, for instance, heart failure.
Whereas the more clinical diagnosis of CHF fails to be an independent risk factor for stroke in AF patients, a more objective/quantitative approach (eg, LVD) does prove more consistently to be an independent stroke risk factor, but not always. 66 Although almost being ignored in the historical anticoagulation trials of 2 decades ago, most studies identified by our search and the nearly all of the most recent available epidemiological evidence clearly indicate the importance of vascular disease as an significant stroke risk predictor. 66-71 However, it is important to further differentiate vascular disease (eg, aortic disease, peripheral vs. coronary artery disease or myocardial infarction), as the former seems to be the driving force behind vascular disease being an independent stroke risk factor in AF patients. 70 Stroke Risk in AF In recent years, female sex has also been identified as an independent stroke risk factor in some, 15,39,72 but not all 21,25,30 studies. Especially in light of recent developments in both stroke risk stratification and the availability of new oral anticoagulants, resulting into adjusted recommendations for the use of oral anticoagulation further studies for this matter are warranted. 72 Fortunately, readily available clinical risk factors are usually sufficient to adequately commence and review antithrombotic therapy. However, when in doubt, echocardiography can assist . 26,34,37,38,41,73 Transthoracic echocardiography might show left ventricular hypertrophy, in the absence of aortic valve stenosis possibly reflecting end-organ damage caused be (undetected or masked) hypertension. Similarly, it might show a reduced left ventricular ejection fraction without the (clear) clinical syndrome of heart failure. A transesophageal echocardiogram 26,37 adds further valuable data because it provides even more (reliable) local information on aspects such as vascular disease (aortic plaques) and structural heart disease (atrial dilatation). However, up to now there has been insufficient recent evidence to support the use of left atrial dimension as a stroke risk factor.
Although the searches identified a few recent studies that considered laboratory data/biomarkers as stroke risk factors, none of those studied parameters was found to be an independent predictor of stroke. Still, there is reason to be optimistic about the future possibilities of biomarkers when considering the prevention of AF-related stroke in the broadest sense. 74 Regarding the health economics analyses, the quality of the studies were good and suggests that OAC is cost-effective in patients at moderate to high risk of stroke, 53-61 but that appears not to be so for those low-risk patients, for whom aspirin seems cost-effective, 55 although the option of no antithrombotic therapy as an alternative in this subset has not been tested. The new oral direct thrombin inhibitor, dabigatran, appears to be cost-effective in high risk patients and also those at moderate risk of stroke; 63-65 however, actual cost price and the individual TTR may also be important factors that influence the latter consideration. Furthermore, limited data on the other new oral anticoagulants, rivaroxaban and apixaban, have been published recently. 75, 76 Even more data 77-79 and comparative efforts are awaited to facilitate optimal decision making in the antithrombotic management of AF patients.
We emphasize that the focus of this review was on stroke risk assessment. However, at the same time we also acknowledge the well-known fact that the risk of stroke and major bleeding go, to some extent, hand in hand and the latter therefore also needs to be considered when dealing with antithrombotic therapy.
Recently, a novel user-friendly risk score called HAS-BLED was introduced. 80 The backbone of this bleeding risk stratification tool was derived from the literature on risk factors of anticoagulation-related to major bleeding which was systematically searched and appraised. 81 It underwent additional fine-tuning and validation in a large European cohort of AF patients and further validations have recently been published, 82,83 contributing to its incorporation into the latest European guidelines on the management of AF. 17 Another bleeding risk assessment tool, the ATRIA bleeding score, 84 consists of 5 weighted factors, but appears to be less user-friendly and was recently outperformed by the HAS-BLED score regarding predictive ability for major bleeding. 83 More importantly, the goal of HAS-BLED or any other practical bleeding risk tool is not to provide a cut-off for when not to commence or continue antithrombotic therapy. It serves as a reminder to all physicians dealing with antithrombotic drugs in AF patients of the risk factors for major bleeding and hopefully triggers appropriate prevention or active treatment to reduce risk. This approach seems very helpful, given the new oral anticoagulants 6-8 and the recent evidence, both from clinical 9 and 'real-world' data, 11,85 that further support the limited role of aspirin as a suitable, safe alternative to OAC.
Study Limitations
The presented review data consists of epidemiological, cohort and clinical studies, all of which were not free from selection bias, to a substantial degree in some cases. Especially regarding the clinical studies, we must keep in mind that only a small minority of the screened patients were actually randomized and therefore included in the data presented. Furthermore, certain conditions (eg, vascular disease) were not consistently recorded or taken into account. Altogether, this could very well affect the relative risk of each of the considered risk factors. Only one of the recent studies made an attempt to consider the not uncommon scenario of coexistence of multiple stroke risk factors in a patient by providing some data on the cumulative risk vs. the risk of stand-alone risk factors. Optimal discrimination between risk strata, the absence of overlap of the respective CIs, was observed for 3 RSMs. Regarding the presented discriminative capability between RSMs, we must be aware that not all methods of calculating the c-statistic provide adequate discrimination levels, as well as that cross-study comparison being impaired by the differences in study populations. Finally, because of the heterogeneity of studies included in the systematic review, a meta-analysis of the data was not feasible.
Conclusion
The importance of stroke prevention in AF has lead to worldwide focus on this topic, resulting in an (ever) increasing body of evidence on stroke risk factors and the development and validation of stroke RSMs. Recognizing the importance of establishing individual profiles through risk factor-based assessment for both risk of stroke and major bleeding, and to develop an integrative ('net clinical benefit') approach, is pivotal to reducing adverse clinical events in patients with AF.
Perhaps the best option is the clinical practice shift that is strongly recommended in the new 2012 focussed update of the European Society of Cardiology guidelines on atrial fibrillation, which is towards more focus on identification of 'truly low-risk' patients with AF (that is, 'age <65 and lone AF (irrespective of gender) or CHA2DS2-VASc score=0'), who do not need any antithrombotic therapy) instead of trying to focus on identifying 'high-risk' patients. 92 
